Royal Bank of Canada’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $23K | Sell |
17,230
-7,661
| -31% | -$13.7K | ﹤0.01% | 5844 |
|
|
2025
Q4 | $46K | Buy |
24,891
+1,633
| +7% | +$3.14K | ﹤0.01% | 5602 |
|
|
2025
Q3 | $29K | Sell |
23,258
-19,589
| -46% | -$26.5K | ﹤0.01% | 6051 |
|
|
2025
Q2 | $52K | Sell |
42,847
-4,078
| -9% | -$4.71K | ﹤0.01% | 5904 |
|
|
2025
Q1 | $55K | Sell |
46,925
-4,534
| -9% | -$6.96K | ﹤0.01% | 5534 |
|
|
2024
Q4 | $94K | Buy |
51,459
+23,543
| +84% | +$46K | ﹤0.01% | 5371 |
|
|
2024
Q3 | $48K | Sell |
27,916
-16,386
| -37% | -$26.9K | ﹤0.01% | 5718 |
|
|
2024
Q2 | $60K | Sell |
44,302
-74,856
| -63% | -$151K | ﹤0.01% | 5565 |
|
|
2024
Q1 | $447K | Sell |
119,158
-92,617
| -44% | -$542K | ﹤0.01% | 4052 |
|
|
2023
Q4 | $2.08M | Buy |
211,775
+14,072
| +7% | +$115K | ﹤0.01% | 3051 |
|
|
2023
Q3 | $1.65M | Buy |
197,703
+50,566
| +34% | +$578K | ﹤0.01% | 3022 |
|
|
2023
Q2 | $1.96M | Buy |
147,137
+38,684
| +36% | +$470K | ﹤0.01% | 2853 |
|
|
2023
Q1 | $1.25M | Sell |
108,453
-34,363
| -24% | -$342K | ﹤0.01% | 3170 |
|
|
2022
Q4 | $1.17M | Sell |
142,816
-94,454
| -40% | -$814K | ﹤0.01% | 3372 |
|
|
2022
Q3 | $1.38M | Buy |
237,270
+13,757
| +6% | +$78.9K | ﹤0.01% | 3156 |
|
|
2022
Q2 | $988K | Buy |
223,513
+160,667
| +256% | +$976K | ﹤0.01% | 3520 |
|
|
2022
Q1 | $572K | Buy |
62,846
+768
| +1% | +$8.84K | ﹤0.01% | 4177 |
|
|
2021
Q4 | $1.27M | Sell |
62,078
-18,802
| -23% | -$454K | ﹤0.01% | 3572 |
|
|
2021
Q3 | $2.06M | Buy |
80,880
+24,943
| +45% | +$739K | ﹤0.01% | 3047 |
|
|
2021
Q2 | $1.96M | Buy |
55,937
+27,364
| +96% | +$796K | ﹤0.01% | 3088 |
|
|
2021
Q1 | $952K | Buy |
28,573
+4,547
| +19% | +$159K | ﹤0.01% | 3637 |
|
|
2020
Q4 | $623K | Sell |
24,026
-34,995
| -59% | -$595K | ﹤0.01% | 3947 |
|
|
2020
Q3 | $583K | Buy |
59,021
+57,406
| +3,555% | +$330K | ﹤0.01% | 3730 |
|
|
2020
Q2 | $5K | Sell |
1,615
-10,267
| -86% | -$35K | ﹤0.01% | 6042 |
|
|
2020
Q1 | $36K | Buy |
11,882
+4,782
| +67% | +$19.6K | ﹤0.01% | 5309 |
|
|
2019
Q4 | $36K | Sell |
7,100
-192,024
| -96% | -$976K | ﹤0.01% | 5600 |
|
|
2019
Q3 | $1.03M | Sell |
199,124
-28,986
| -13% | -$162K | ﹤0.01% | 3331 |
|
|
2019
Q2 | $1.38M | Buy |
228,110
+222,252
| +3,794% | +$1.56M | ﹤0.01% | 3050 |
|
|
2019
Q1 | $42K | Buy |
5,858
+2,143
| +58% | +$15.5K | ﹤0.01% | 5257 |
|
|
2018
Q4 | $27K | Sell |
3,715
-2,827
| -43% | -$17.9K | ﹤0.01% | 5433 |
|
|
2018
Q3 | $35K | Buy |
6,542
+2,606
| +66% | +$11.2K | ﹤0.01% | 5405 |
|
|
2018
Q2 | $14K | Buy |
3,936
+205
| +5% | +$569 | ﹤0.01% | 5708 |
|
|
2018
Q1 | $8K | Sell |
3,731
-585
| -14% | -$1.52K | ﹤0.01% | 5796 |
|
|
2017
Q4 | $12K | Sell |
4,316
-13,943
| -76% | -$48.8K | ﹤0.01% | 5798 |
|
|
2017
Q3 | $96K | Buy |
18,259
+14,383
| +371% | +$61.8K | ﹤0.01% | 5046 |
|
|
2017
Q2 | $14K | Sell |
3,876
-3,395
| -47% | -$13.7K | ﹤0.01% | 5681 |
|
|
2017
Q1 | $38K | Buy |
7,271
+338
| +5% | +$1.65K | ﹤0.01% | 5294 |
|
|
2016
Q4 | $27K | Buy |
6,933
+5,418
| +358% | +$39.4K | ﹤0.01% | 5604 |
|
|
2016
Q3 | $14K | Buy |
1,515
+300
| +25% | +$2.51K | ﹤0.01% | 5675 |
|
|
2016
Q2 | $9K | Hold |
1,215
| – | – | ﹤0.01% | 5784 |
|
|
2016
Q1 | $10K | Sell |
1,215
-476
| -28% | -$4.68K | ﹤0.01% | 5735 |
|
|
2015
Q4 | $22K | Sell |
1,691
-1,378
| -45% | -$12.4K | ﹤0.01% | 5676 |
|
|
2015
Q3 | $11K | Sell |
3,069
-310
| -9% | -$1.52K | ﹤0.01% | 5850 |
|
|
2015
Q2 | $19K | Buy |
+3,379
| New | +$19.6K | ﹤0.01% | 5727 |
|
|
2013
Q4 | – | Sell |
-2,000
| Closed | -$11K | – | 6074 |
|
|
2013
Q3 | $11K | Hold |
2,000
| – | – | ﹤0.01% | 5377 |
|
|
2013
Q2 | $5K | Buy |
+2,000
| New | +$4.98K | ﹤0.01% | 5449 |
|
Other funds holding PACB
AIM
VCM
NAMA
Royal Bank of Canada's PACB Position: Q1 2026 in Review
Royal Bank of Canada reduced its Pacific Biosciences (PACB) stake by 31% in Q1 2026, selling an estimated $13.7K and leaving 17,230 shares worth $23K. The position accounts for ﹤0.01% of the portfolio, ranked #5844.
Royal Bank of Canada first reported a position in PACB in Q2 2013 and has held it in 46 quarters since. The position peaked at $2.08M in Q4 2023. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.
- Royal Bank of Canada held 17,230 shares of Pacific Biosciences worth $23K as of Q1 2026.
- Royal Bank of Canada sold 7,661 Pacific Biosciences shares in Q1 2026, an estimated $13.7K.
- Pacific Biosciences made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5844 holding.
- Royal Bank of Canada first reported a position in Pacific Biosciences in Q2 2013 and has held it in 46 quarters since.
- Royal Bank of Canada's Pacific Biosciences position peaked at $2.08M in Q4 2023.
- 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.